BVS - MedTech Bioventus' Stabilization Sparks Analyst Confidence Earns Upgrade And Price Target Boost | Benzinga
Canaccord Genuity has upgraded Biomedical Devices and Services company Bioventus Inc (NASDAQ: BVS), highlighting greater insight into the progress of the turnaround and plans for future investment and growth.
The analyst notes that the business is now stabilized, and management is discussing strategic investments in the existing business to drive future growth.
Management expects that the worst of challenges are likely behind the company.
Canaccord indicates that the management anticipates that the continual investments made in its Exogen business during the past few years will enhance the quality of the product.
They foresee that the effectiveness of the ...